How Can Bcl-2 Family Proteins Be Targeted for Cancer Therapy?
Targeting Bcl-2 family proteins has emerged as a promising strategy for cancer therapy. Several approaches are being explored: 1. BH3 Mimetics: These are small molecules designed to mimic the activity of pro-apoptotic BH3-only proteins, thereby antagonizing the anti-apoptotic members. ABT-199 (Venetoclax) is a notable example used in the treatment of chronic lymphocytic leukemia (CLL). 2. Antisense Oligonucleotides: These molecules can specifically bind to the mRNA of anti-apoptotic proteins, preventing their translation and leading to reduced protein levels. 3. Combination Therapies: Combining BH3 mimetics with other treatments like chemotherapy or targeted therapies can enhance the efficacy by simultaneously attacking cancer cells through multiple pathways.
